[CAS NO. 501935-96-2] CTX1
PRODUCTS SPECIFICATIONS [501935-96-2]
DESCRIPTION [501935-96-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 234.26 |
| Molecular Formula | C14H10N4 |
| SMILES | N#CC1=C(C=CC(N)=C2)C2=NC3=CC(N)=CC=C31 |
1 Publications Citing Use of MCE
Summary
CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system [1] .
IC50 & Target
p53 [1]
In Vitro
CTX1 binds directly to HdmX to prevent p53-HdmX complex formation, resulting in the rapidly induction of p53 in a DNA damage-independent manner
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
CTX1 ( (30 mg/kg; i.p.; five days a week; for 3 weeks) significantly enhances the survival of mice in AML model system
[1]
.
CTX1 exhibited significant anti-cancer activity alone as well as in combination with nutlin-3
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 12.5 mg/mL ( 53.36 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.2688 mL | 21.3438 mL | 42.6876 mL |
| 5 mM | 0.8538 mL | 4.2688 mL | 8.5375 mL |
| 10 mM | 0.4269 mL | 2.1344 mL | 4.2688 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 1.25 mg/mL (5.34 mM); Suspended solution; Need ultrasonic